Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. Filtered by score tier "Strong", market "Europe (incl. UK)", Has report: 11 match(clear filters).

# Ticker Mkt Cap Score 10Y ROE Profit Streak Net Debt/Eq Gross Margin Report FY
1 Novartis AG NOVN · SW $306B
78/100 Strong
20.9%low 9.0% 10 yr+ 0.6× 71% Novartis (NVS) Zen Horizon Research ReportJun 8, 2026 · Hold FY2025
2 ABB Ltd ABBN · SW $183B
77/100 Strong
21.9%low 8.1% 10 yr+ 0.2× 33% ABB Ltd Zen Horizon Framework Deep ResearchJun 6, 2026 · Watch FY2025
3 Thales S.A. HO · Paris $55B
77/100 Strong
16.8%low 9.5% 10 yr+ 0.2× 25% Thales: A Genuine Defence-Electronics Quality Compounder, Priced Like the Best Case Is Already Locked InJul 7, 2026 · Hold FY2025
4 Eckert & Ziegler Strahlen- und Medizintechnik AG EUZ · XETRA $1.0B
76/100 Strong
14.4%low 9.1% 10 yr+ Net cash 48% Eckert & Ziegler SE: A Better Business, Not Yet a Better PriceJul 15, 2026 · Hold FY2025
5 Intertek Group PLC ITRK · LSE $11B
75/100 Strong
30.4%low 22.5% 10 yr+ 1.2× 32% Intertek: Quality Compounder on a Takeover BidJun 17, 2026 · Hold FY2025
6 SGS SA SGSN · SW $24B
74/100 Strong
48.5%low 30.6% 10 yr+ 3.3× 48% SGS: High-Quality TIC Compounder at Full ValueJun 17, 2026 · Hold FY2025
7 UCB SA UCB · BR $45B
71/100 Strong
10.2%low 3.8% 10 yr+ Net cash 71% UCB SA: A Specialty-Biopharma Growth Platform That Has Already Re-RatedJun 29, 2026 · Hold FY2025
8 Bureau Veritas SA BVI · Paris $13B
70/100 Strong
27.2%low 10.1% 10 yr+ 1.0× 30% Bureau Veritas: Quality TIC, Priced for ReaccelerationJun 17, 2026 · Hold FY2025
9 Schneider Electric S.E. SU · Paris $176B
68/100 Strong
12.5%low 8.5% 10 yr+ 0.6× 40% Schneider Electric (SU.PA) Zen Horizon Research ReportJun 5, 2026 · Watch FY2025
10 ASM International NV ASM · Amsterdam $42B
67/100 Strong
16.8%low 6.7% 10 yr+ Net cash 47% ASM International Deep Value Investment AnalysisJun 4, 2026 · Watch FY2025
11 Hexagon AB (publ) HEXA-B · ST $25B
67/100 Strong
10.6%low 6.0% 10 yr+ 0.3× 64% Hexagon AB (HEXA-B.ST) Zen Horizon Deep-Dive Research ReportJun 9, 2026 · Watch FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.